Understanding the Role of AMPK Function in PPHN

Persistent Pulmonary Hypertension of the Newborn (PPHN) remains a significant clinical challenge in neonatology. While high pulmonary vascular resistance is a hallmark, the underlying mechanisms of vascular remodeling are still being elucidated. Recent research indicates that a deficiency in AMPK function in PPHN plays a central role in this process. 5'AMP-Activated Protein Kinase (AMPK) acts as a metabolic master switch. When its activity decreases in pulmonary artery smooth muscle cells (PASMCs), it triggers a cascade of cellular dysfunction. This reduction in signaling leads to impaired mitochondrial capacity and structural changes in the pulmonary vasculature.

Mechanisms of Mitochondrial Dysfunction and Remodeling

The study utilized fetal lamb models to investigate how decreased AMPK function in PPHN impacts neonatal lung health. Researchers found that reduced levels of phosphorylated AMPK (p-AMPK) were associated with a decline in PGC-1\u03b1 and mitochondrial electron transport chain (ETC) complexes. Consequently, this metabolic shift reduces the oxidative phosphorylation capacity of PASMCs. Furthermore, the loss of AMPK signaling affects the Notch pathway, specifically decreasing the expression of ligands like Jag1 and Hey1. These changes promote a shift from differentiated to dedifferentiated PASMC phenotypes, characterized by reduced MYH11 and increased vimentin levels, which drive vascular remodeling.

Therapeutic Potential of Metformin

One of the most promising aspects of this research is the potential for therapeutic intervention. The study explored the effects of AMPK agonists, such as metformin and A769662, both in vitro and in vivo. These agents successfully increased the expression of PGC-1\u03b1 and ETC complexes in PPHN PASMCs. In animal models, metformin treatment helped restore Notch signaling and improved the differentiation status of smooth muscle cells. These findings suggest that targeting AMPK function in PPHN could offer a novel strategy for mitigating the long-term structural damage associated with neonatal pulmonary hypertension.

FAQs on AMPK and PPHN

What is the clinical significance of AMPK in neonatal lungs?

AMPK is essential for maintaining cellular energy balance. In PPHN, its downregulation leads to mitochondrial failure and abnormal smooth muscle cell growth, contributing to the thickening of pulmonary vessel walls.

How does metformin affect pulmonary vascular remodeling?

Metformin acts as an AMPK activator. By restoring AMPK signaling, it enhances mitochondrial biogenesis and normalizes the Notch pathway, which helps prevent the pathological remodeling of pulmonary arteries.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Mooers EA et al. Decreased AMP-Kinase Function in Pulmonary Artery Smooth Muscle Cells Contributes to Pulmonary Artery Remodeling in Persistent Pulmonary Hypertension of Newborn. Am J Physiol Lung Cell Mol Physiol. 2026 Feb 25. doi: 10.1152/ajplung.00229.2025. PMID: 41740187.

2. Rana U et al. AMP-Kinase dysfunction alters notch ligands to impair angiogenesis in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2022. doi: 10.1152/ajplung.00067.2022.

3. Evans AM et al. AMPK deficiency in smooth muscles causes persistent pulmonary hypertension after birth and premature death. bioRxiv. 2022. doi: 10.1101/2022.06.11.495744.